Literature DB >> 10933310

Increased adipose angiotensinogen gene expression in human obesity.

V Van Harmelen1, P Ariapart, J Hoffstedt, I Lundkvist, S Bringman, P Arner.   

Abstract

OBJECTIVE: Adipose angiotensinogen has been suggested as a stimulator of adipose tissue growth and development. Therefore, the association of subcutaneous adipose angiotensinogen gene expression with human obesity was studied. RESEARCH METHODS AND PROCEDURES: The study group consisted of 17 men, undergoing either gastric banding for obesity or elective laparoscopic cholecystectomy (7 obese, 10 non-obese men; body mass index 22 to 51 kg/m2; age 26 to 68 years). Subcutaneous adipose angiotensinogen mRNA and 18S ribosomal RNA (reference gene) levels were measured using competitive quantitative reverse transcriptase-polymerase chain reaction.
RESULTS: Adipose angiotensinogen mRNA expression was about two times increased in obesity. The levels of 18S rRNA did not differ between the two groups. Body weight correlated independently and positively with adipose angiotensinogen mRNA expression after adjusting for differences in age and height. DISCUSSION: Adipose angiotensinogen gene expression is elevated in obesity in men.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933310     DOI: 10.1038/oby.2000.40

Source DB:  PubMed          Journal:  Obes Res        ISSN: 1071-7323


  41 in total

Review 1.  New developments in mechanisms of obesity-induced hypertension: role of adipose tissue.

Authors:  A M Sharma; S Engeli; T Pischon
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

Review 2.  Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications.

Authors:  Graziela Z Kalil; William G Haynes
Journal:  Hypertens Res       Date:  2011-11-03       Impact factor: 3.872

Review 3.  Obesity and adipokines: effects on sympathetic overactivity.

Authors:  Michael M Smith; Christopher T Minson
Journal:  J Physiol       Date:  2012-02-20       Impact factor: 5.182

Review 4.  The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome.

Authors:  Tina Thethi; Masumi Kamiyama; Hiroyuki Kobori
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

5.  Polymorphism in miR-31 and miR-584 binding site in the angiotensinogen gene differentially influences body fat distribution in both sexes.

Authors:  Jan Machal; Jan Novak; Renata Hezova; Filip Zlamal; Anna Vasku; Ondrej Slaby; Julie Bienertova-Vasku
Journal:  Genes Nutr       Date:  2015-08-26       Impact factor: 5.523

6.  Aliskiren combined with losartan: Thor's hammer or Sigurd's sword?

Authors:  Thomas R Lux; Heinrich Taegtmeyer
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

Review 7.  Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training.

Authors:  Christian K Roberts; Andrea L Hevener; R James Barnard
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

8.  Human adipose angiotensinogen gene expression and secretion are stimulated by cyclic AMP via increased DNA cyclic AMP responsive element binding activity.

Authors:  Valérie Serazin; Esther Dos Santos; Mireille Morot; Yves Giudicelli
Journal:  Endocrine       Date:  2004-11       Impact factor: 3.633

Review 9.  Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications.

Authors:  Jonathan G Owen; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

10.  Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.

Authors:  Hiroaki Masuzaki; Hiroshi Yamamoto; Christopher J Kenyon; Joel K Elmquist; Nicholas M Morton; Janice M Paterson; Hiroshi Shinyama; Matthew G F Sharp; Stewart Fleming; John J Mullins; Jonathan R Seckl; Jeffrey S Flier
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.